Kuva Labs, a specialist in cancer imaging, has entered into a binding agreement to acquire Lisata Therapeutics, a biotech firm focused on advanced solid tumors. The acquisition centers on certepetide, a promising Phase 2-stage investigational drug.
Transaction Details and Shareholder Value Kuva Labs has offered $4.00 per share in cash for Lisata, representing an 85% premium over its previous closing price.
-
Contingent Value Rights (CVRs): Stockholders are eligible for an additional $2.00 per share in potential payouts.
-
Milestone Triggers: These payments are tied to Kuva reacquiring the Greater China rights for certepetide from Qilu Pharmaceutical and the successful submission of a New Drug Application (NDA) in any jurisdiction.
The Science of Certepetide Certepetide (formerly CEND-1) is a cyclic peptide utilizing the proprietary CendR Platform technology.
-
Mechanism of Action: The peptide undergoes protease-mediated cleavage within the tumor microenvironment, releasing a “CendR” fragment that facilitates transport across the dense tumor stroma.
-
Therapeutic Benefit: By breaking through this physical barrier, the drug enhances the penetration and accumulation of co-administered anti-cancer agents. It is currently being evaluated for difficult-to-treat cancers, including pancreatic, biliary tract, and appendiceal cancers.
Strategic Synergy The acquisition follows a successful November 2024 licensing deal where Kuva utilized certepetide to enhance its NanoMark platform. By combining this targeting agent with high-resolution magnetic resonance imaging (MRI), Kuva aim to develop non-radioactive diagnostic tools capable of identifying early-stage solid tumors with unprecedented clarity. The merger allows Kuva to vertically integrate targeted diagnostics with potential therapeutic applications.